Hutton's__O research__O on__O the__O effects__O of__O selection__O bias__O includes__O development__O of__O new__O statistical__O methods,__O and__O consequently__O direct__O application__O of__O the__O results__O to__O particular__O diseases__O and__O treatments,__O and__O to__O the__O implications__O for__O good__O conduct__O and__O reporting__O of__O studies.__O
The__O impact__O has__O therefore__O been__O in__O three__O areas:__O A)__B-MISC Specific__I-MISC clinical__O guidance__O on__O the__O treatment__O of__O epilepsy__O Epilepsy__O is__O a__O common__O neurological__O disorder__O affecting__O over__O 500,000__O people__O within__O the__O UK__B-ORG (http://www.nhs.uk/Conditions/Epilepsy/Pages/Introduction.aspx).__I-ORG
In__O around__O 70%__O of__O cases,__O seizures__O are__O successfully__O controlled__O by__O AEDs__B-ORG (anti-epileptic__O drugs)__O which__O are__O the__O 5th__O highest__O category__O of__O expenditure__O on__O NHS__B-LOC England__I-LOC prescriptions.__O
The__O 2004__O NICE__B-ORG (National__O Institute__B-ORG for__I-ORG Health__I-ORG and__I-ORG Clinical__I-ORG Excellence)__I-ORG Guidelines__I-ORG for__I-ORG the__I-ORG Diagnosis__I-ORG and__I-ORG Management__I-ORG of__I-ORG Epilepsy__I-ORG highlighted__O inadequacies__O in__O care__O and__O treatment__O of__O epilepsy__O patients.__O
In__O 2007__O a__O major__O multi-centre__O study__O SANAD__B-ORG (Standard__I-ORG and__O New__B-MISC Antiepileptic__I-MISC Drugs),__I-MISC which__O compared__O the__O clinician's__O choice__O of__O drug__O against__O new__O AEDs__B-MISC in__O over__O 2,000__O patients,__O was__O published.__O
The__O design__O of__O this__O trial,__O led__O by__O UoL,__B-ORG was__O determined__O by__O Hutton's__B-ORG research.__O
Her__O analyses__O had__O highlighted__O uncertainty__O with__O regard__O to__O interactions__O between__O drugs,__O and__O patient__O factors__O of__O age,__O type__O of__O epilepsy__O and__O seizure__O type__O related__O to__O misclassification__O bias__O [6,__O 8].__O
The__O significance__O of__O the__O SANAD__B-MISC trial__O is__O considerable,__O e.g.__O
:__O SANAD__O played__O a__O central__O role__O in__O the__O construction__O of__O the__O 2012__O NICE__B-ORG Guidelines__O [12a],__O "The__O primary__O scope__O of__O the__O guidelines__O was__O to__O consider__O the__O role__O of__O antiepileptic__O drugs,__O especially__O given__O the__O impact__O of__O important,__O real-world__O studies__O such__O as__O SANAD.__B-ORG
The__O role__O of__O established__O and__O newly__O licensed__O drugs__O has__O been__O considered__O using__O novel__O statistical__O methods__O allowing__O comparison__O of__O cost__O effectiveness"__O (Preface__B-ORG P3).__I-ORG
The__O Guidelines__O are__O important__O since__O they__O are__O "expected__O to__O be__O taken__O into__O full__O consideration__O by__O healthcare__O professionals__O and__O organisations__O when__O deciding__O on__O treatments__O for__O patients"__O [12b].__B-MISC
A__O Consultant__O in__O Neuropsychiatry__O [12c]__O states__O that__O "SANAD__O is__O the__O best__O clinical__O trial__O and__O is__O the__O gold__O standard__O piece__O of__O work__O in__O relation__O to__O the__O treatment__O of__O epilepsy.__O
It__O is__O referred__O to__O in__O the__O NICE__B-ORG guidelines__O for__O good__O reason.__O
The__O other__O main__O strength__O of__O SANAD__B-ORG is__O that__O it__O was__O not__O constrained__O by__O the__O needs__O of__O the__O pharmaceutical__O industry__O and__O has__O the__O reputation__O of__O being__O relatively__O bias-free".__O
The__O World__B-ORG Health__I-ORG Organisation__I-ORG (WHO)__I-ORG guidelines__O "Evidence-based__B-MISC recommendations__O for__O management__O of__O epilepsy__O and__O seizures__O ..."__O cite__O the__O meta-analysis__O [13a].__O
In__O addition,__O in__O [13b],__O the__O SANAD__B-ORG trial__O results__O were__O explicitly__O highlighted__O when__O WHO__B-ORG deliberated__O whether__O to__O allow__O the__O application__O for__O a__O new__O epilepsy__O drug__O treatment__O regime.__O
SANAD__O trial__O results__O were__O used__O in__O a__O WHO__B-ORG decision__O not__O to__O include__O Lamotrigine__O for__O epilepsy__O in__O their__O Model__B-ORG List__I-ORG of__I-ORG Essential__I-ORG Medicines.__I-ORG
SANAD__O determined__O the__O recommendations__O of__O the__O German__B-ORG Association__I-ORG of__I-ORG Scientific__I-ORG Medical__O Societies,__O for__O AEDs__O to__O be__O used__O to__O treat__O first__O seizures__O and__O epilepsy__O in__O adults__O [14].__O
The__O Scottish__B-MISC Intercollegiate__O Guidelines__O Network__O [15]__O cites__O meta-analyses__O (eg__O [8])__O by__O Hutton__B-ORG as__O justification__O for__O its__O treatment__O recommendations.__O
Hutton__B-PER was__O instructed__O [text__O removed__O for__O publication],__O as__O an__O expert__O witness__O for__O the__O claimants__O in__O a__O multi-party__O class__O action__O [text__O removed__O for__O publication],__O after__O which__O the__O case__O was__O concluded__O with__O a__O confidential__O out-of-court__O settlement.__O
B)__O Generic__O guidance__O for__O the__O conduct__O and__O reporting__O of__O biomedical__O research__O There__O are__O many__O examples__O where__O Hutton's__B-MISC research__O [3,__O 4,__O 5]__O has__O been__O cited__O and__O used__O inter__O alia__O by__O policy__O makers,__O journal__O editors,__O and__O potential__O study__O participants,__O to__O provide__O guidance__O on__O the__O ethical__O design__O and__O conduct__O of__O cluster__O randomised__O trials,__O including__O the__O following__O examples.__O
1.__O
Impacts__O on__O guidelines__O for__O statistical__O validity__O and__O ethics__O in__O cluster__O randomised__O trials__O [4,5]__O include:__O One__O of__O the__O MRC's__B-MISC clinical__O trials__O guidelines__O "Cluster__B-ORG Randomised__I-ORG Trials:__I-ORG Methodological__I-ORG and__O Ethical__B-ORG Considerations"__I-ORG [17]__I-ORG is__O based__O largely__O on__O the__O research__O in__O [4].__O
Recommendations__O (from__O [4,__O 5])__O are__O also__O incorporated__O into__O the__O Consolidated__B-ORG Standards__I-ORG of__I-ORG Reporting__I-ORG Trials__I-ORG (CONSORT)__I-ORG Design__I-ORG extension__O to__O cluster__O randomised__O trials__O [18].__O
CONSORT__O is__O in__O turn__O included__O within__O the__O International__B-ORG Committee__I-ORG of__I-ORG Medical__I-ORG Journal__I-ORG Editors__I-ORG (ICMJE)__I-ORG recommendations__O [19].__O
Recommendations__O (from__O [4,__O 5])__O are__O also__O incorporated__O into__O the__O Ottawa__B-ORG Statement__I-ORG on__O the__O Ethical__B-ORG Design__I-ORG and__I-ORG Conduct__I-ORG of__I-ORG Cluster__I-ORG Randomized__I-ORG Trials__I-ORG [20].__I-ORG
2.__O
Preferred__B-ORG Reporting__I-ORG Items__I-ORG for__I-ORG Systematic__I-ORG Reviews__I-ORG and__I-ORG Meta-Analyses__I-ORG (PRISMA)__I-ORG [21]__O is__O an__O evidence-based__O checklist__O for__O reporting__O systematic__O reviews__O and__O meta-analysis,__O which__O has__O been__O translated__O into__O Spanish,__B-MISC Korean__I-MISC and__O Russian.__B-LOC
Its__O recommendations__O are__O also__O incorporated__O into__O the__O ICMJE__B-ORG [19]__O to__O which__O most__O biomedical__O journals__O subscribe,__O and__O thus__O whose__O authors__O must__O comply__O with__O each__O item__O on__O a__O specified__O checklist.__O
Hutton's__O work__O in__O [3]__O contributed__O to__O two__O check__O points__O related__O to__O selective__O reporting__O within__O studies.__O
3.__O
Research__O led__O by__O Hutton__B-PER for__O the__O National__B-LOC Centre__I-LOC for__O the__O Replacement,__O Refinement__O and__O Reduction__B-ORG of__I-ORG Animals__I-ORG in__I-ORG Research__I-ORG attracted__I-ORG media__O coverage,__O and__O contributed__O to__O reporting__O guidelines__O in__O Animal__B-ORG Research:__I-ORG Reporting__I-ORG of__I-ORG In__I-ORG Vivo__I-ORG Experiments__O (ARRIVE)__O [22a].__O
This__O is__O endorsed__O by__O many__O journals__O and__O ten__O funders,__O including__O the__O Wellcome__B-LOC Trust__I-LOC and__O three__O research__O councils__O [22b].__O
C)__O Evidence__O given__O in__O other__O trial__O cases__O as__O an__O expert__O witness__O Based__B-ORG on__O her__O research__O on__O selection__O bias,__O ethics__O and__O meta-analysis,__O Hutton__B-PER has__O made__O recent__O appearances__O as__O an__O expert__O witness__O in__O legal__O cases.__O
They__O include:__O The__O General__B-ORG Medical__I-ORG Council__I-ORG instructed__I-ORG Hutton__I-ORG in__O May__O 2008__O in__O a__O case__O concerning__O the__O conduct,__O design,__O choice__O and__O reporting__O of__O outcome__O measures__O of__O a__O clinical__O trial__O for__O which__O three__O doctors__O were__O accused__O of__O professional__O misconduct__O [23].__O
The__O case__O 'collapsed__O because__O it__O had__O no__O sound__O scientific__O evidence__O to__O support__O it'__O [23],__O as__O a__O direct__O result__O of__O Hutton's__B-MISC discussions__O with__O the__O GMC__B-ORG and__O her__O report__O based__O on__O her__O research__O including__O [1,2].__B-ORG
Based__O on__O her__O work__O including__O [3,__O 7,__O 9],__O Hutton__B-PER was__O [text__O removed__O for__O publication]__O (over__O 100__O cases)__O [24a,__B-ORG 24b,__O 24c].__O
